Drug stocks can be somewhat volatile. Things like clinical setbacks or patent cliffs can sink their stock prices or erode their profits and market share. However, one good thing about companies in this industry is that there will always be a need for innovative medicines, which remain in high demand regardless of economic conditions. That makes drugmakers, particularly the best ones capable of consistently developing new products, attractive long-term holdings. Let's consider three, in particular, that look ...

Core Viewpoint - The innovation of semaglutide for diabetes and obesity is considered a game-changing moment in weight management globally, including in India [1] Group 1: Product Launch and Market Dynamics - Semaglutide was launched as an injectable product less than a year ago, and the company is now facing generic competition, which is seen as a necessary change [2] - The company reduced the pricing of semaglutide by 37% to cater to the patient population in India, reflecting a patient-centric approach [3] - The access to these medications has significantly increased in India over the past four to five months due to the price reduction [4] Group 2: Manufacturing and Quality Assurance - The company emphasizes the quality of its products, including the RNA and RDNA-based manufacturing process, which is imported from Denmark [4] - The company has world-class fill and packaging facilities, ensuring that the science and technology behind the product justify the pricing after the reduction [5] Group 3: Distribution and Accessibility - Partnerships with companies like Mure and Abbott are aimed at expanding the reach of semaglutide in tier two and tier three cities in India [6][7] - The increasing number of endocrinologists and internal medicine doctors in these cities is enhancing access to diabetes and obesity treatments [8] - There is a notable shift in the prescription of insulin from urban to rural areas, indicating a potential similar trend for GLP-1 medications like semaglutide [9]

Novartis agrees to buy an experimental breast cancer drug for as much as $3 billion https://t.co/K00VXr6BDx ...

Ozempic copies will cost as low as $14 in India as the era of generic GLP-1 begins https://t.co/jUxzRfWFFM ...

Core Insights - Novartis is evaluating SNV4818 in early and mid-stage studies for breast cancer and other advanced solid tumors [1] Company Overview - The focus of Novartis on SNV4818 indicates a strategic investment in oncology research, particularly targeting breast cancer and advanced solid tumors [1]

Core Viewpoint - Novartis has agreed to acquire the breast cancer drug candidate SNV4818 from Synnovation Therapeutics for an upfront payment of $2 billion, with an additional $1 billion contingent on further development achievements [1][2]. Group 1: Acquisition Details - The acquisition involves an upfront payment of $2 billion and potential additional payments of up to $1 billion based on development milestones [1]. - SNV4818 is classified as a selective PI3K inhibitor, representing a new treatment approach for HR positive/HER2 negative breast cancer and potentially other solid tumors [2].

Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818, currently in a Phase 1/2 clinical study, is designed to selectively target PI3Kα mutations in breast cancer while sparing wild-type PI3Kα, thus reducing unwanted side effects and improving tolerabilityAddresses a well‑defined patient population with significant unmet need -- approximately 40% of HR+/HER2- breast canc ...

Core Viewpoint - The article discusses the challenges in finding equity income, highlighting low dividend yields in both the US and global markets, and emphasizes the importance of companies with strong dividend histories and wide economic moats for steady income generation [1][2][4]. Dividend Yield Trends - The Morningstar US Market Index had a dividend yield of under 1.2% in Q1 2026, which is historically low, while the Morningstar Global Markets ex-US Index offered a yield of 2.6% [1]. - Stock prices have increased significantly, but dividend payments have not kept pace, with a notable shift towards share buybacks and investments in artificial intelligence [2]. Sector Performance - There has been a rebound in sectors such as industrials, energy, and consumer defensives, which has supported total returns but kept yields lower [3]. - Dividend-paying stocks outside the U.S. have outperformed the broader market for some time, with around 1,500 companies globally under analyst coverage and assigned moat ratings [3]. Moat Analysis - Companies with wide moats tend to sustain profitability more consistently and have historically cut dividends less often compared to those with narrow or no moats [4]. Methodology for Stock Selection - The selection criteria for the list of dividend stocks included companies that have raised dividends for at least 10 consecutive years and have yields above 0.5% as of March 19 [6]. Company Highlights - **Eli Lilly and Company (NYSE: LLY)**: - Dividend yield as of March 19 is 0.75%. Recent study results for retatrutide indicate it may be a viable option for patients prioritizing weight loss, with projected 2030 sales at $4.9 billion [9][10][11]. - **S&P Global Inc. (NYSE: SPGI)**: - Dividend yield as of March 19 is 0.91%. The price recommendation was raised to $495, citing stronger issuance trends, with February billed issuance rising 22% year-over-year [12][13]. - The acquisition of Enertel AI Corporation enhances S&P Global's capabilities in AI-driven power price forecasting, providing a more comprehensive view of the power market [14][15].

Core Viewpoint - A class action lawsuit has been filed against Soleno Therapeutics, Inc. regarding allegations of securities fraud and unlawful business practices related to its product, DCCR [2][3]. Group 1: Class Action Details - Investors who suffered losses from their investment in Soleno are encouraged to contact Pomerantz LLP to join the class action lawsuit [1]. - The deadline to request appointment as Lead Plaintiff is May 5, 2026, for those who purchased Soleno securities during the Class Period [2]. Group 2: Product and Market Impact - Scorpion Capital published a report on August 15, 2025, labeling DCCR as overpriced and potentially unsafe for children, leading to a stock price drop of $5.73 per share, or 7.41%, closing at $71.63 [2][3]. - Following the disclosure of a patient death related to DCCR on September 10, 2025, Soleno's stock fell by $13.49 per share, or 19.21%, to close at $56.72 [3]. - On November 4, 2025, Soleno reported an 8% discontinuation rate of DCCR due to adverse effects, which the CEO attributed to the negative impact of the Scorpion report on the product's launch trajectory [4]. - The stock price further declined by $16.98 per share, or 26.59%, closing at $46.87 on November 5, 2025 [5].

England’s drug price regulator will have to reconsider its decision to rule out using Eli Lilly’s Alzheimer’s drug in the state-run National Health Service, following a successful appeal by the US drugmaker https://t.co/fWXon8Qsap ...